ClinicalTrials.gg
Active, not recruitingNCT06356129GOLSEEK-1Updated Jul 6, 2026

Study to Compare the Effectiveness and Safety of Golcadomide Plus R-CHOP vs Placebo Plus R-CHOP in Participants With Previously Untreated High-risk Large B-cell Lymphoma

A Phase 3 interventional study of Golcadomide and Placebo in Large B-cell Lymphoma, sponsored by Celgene. Active, not recruiting at 325 sites in 38 countries. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-07-06.

Sponsored by Celgene (part of Bristol-Myers Squibb) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
850
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 42 studies in Lymphoma by Bristol-Myers Squibb — 2 open to participants now, 5 under way, 1 of them phase 3. Lymphoma · Bristol-Myers Squibb.

Planned enrollment
Largest of 39
850 · median 74
Started
2024
with 1 other
Phase 3
5 of 42
none open now
Registered
40th of 42
by date

Among the 42 studies in Lymphoma by Bristol-Myers Squibb, this one has the largest planned enrollment of the 39 interventional ones that give a count, is one of 2 that started in 2024, is one of 5 in phase 3, and was the 40th registered.

Lymphoma

3,018 studies on the registry are indexed under Lymphoma; 433 are open to participants now.

Browse Lymphoma studies →

Open to participants now

2 of the 42 studies in Lymphoma by Bristol-Myers Squibb are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Who these studies take

Of the 346 Lymphoma studies recruiting now, 227 (66%) set no upper age limit and 78 (23%) stop at 75 or younger; 77 take children under 18; 20 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 42 studies in Lymphoma by Bristol-Myers Squibb, or all of them as a file.
02

Study summary

The purpose of this study is to compare the effectiveness and safety of golcadomide in combination with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) chemotherapy vs placebo in combination with R-CHOP chemotherapy in participants with previously untreated high-risk large B-cell lymphoma (LBCL).

03

Conditions studied

  • Large B-cell Lymphoma

Browse trials for

Keywords

  • Lymphoma, Large B-Cell
  • Lymphoma
  • BMS-986369
  • CC-99282
  • DLBCL
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

- confirmed (per local evaluation) diagnosis of de novo, previously untreated large B-cell lymphoma (LBCL) according to 2022 world health organization (WHO) classification including:

i) Diffuse large B-cell lymphoma (DLBCL), not otherwise specified [including germinal center B-cell (GCB) and activated B-cell (ABC) types]

ii) High-grade B-cell lymphoma, with MYC and BCL2 rearrangements (HGBL-MYC/BCL2 double-hit lymphomas)

iii) High-grade B-cell lymphoma, not otherwise specified

iv) T-cell/histiocyte/rich large B-cell lymphoma (THRLBCL)

v) Epstein-Barr virus + DLBCL

  • International Prognostic Index (IPI) score 1 or 2 with lactate dehydrogenase (LDH) > 1.3 x (ULN) and/or bulky disease defined as single lesion of ≥ 7 cm OR IPI ≥ 3.
  • defined by at least 1 fluorodeoxyglucose (FDG)-avid lesion for FDG-avid subtype and 1 bi-dimensionally measurable (> 1.5 cm in longest diameter) disease by computed tomography (CT) or magnetic resonance imaging (MRI), as defined by the Lugano classification.
  • Must have Ann Arbor Stage II-IV disease.

Exclusion criteria

Exclusion Criteria

  • Any significant medical condition, active infection, laboratory abnormality, or psychiatric illness that would prevent the participant from participating in the study.
  • Any other subtype of lymphoma. Cases of primary mediastinal (thymic) large B-cell lymphoma (PMBCL), primary cutaneous DLBCL-leg type, Grade 3b FL, indolent lymphoma transformed to large B-cell lymphoma (LBCL), Anaplastic lymphoma kinase (ALK) positive large B-cell lymphoma, primary effusion lymphoma, and Burkitt lymphoma.
  • Documented or suspected central nervous system (CNS) involvement by lymphoma.
  • Other protocol-defined Inclusion/Exclusion criteria apply.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
850 participants (estimated)

Study arms

  • Experimental
    Golcadomide + R-CHOP (Rituximab, Doxorubicin, Vincristine, Cyclophosphamide, Prednisone)

    Drug: Golcadomide · Drug: Rituximab · Drug: Cyclophosphamide · Drug: Doxorubicin · Drug: Vincristine · Drug: Prednisone

  • Placebo comparator
    Placebo + R-CHOP

    Drug: Placebo · Drug: Rituximab · Drug: Cyclophosphamide · Drug: Doxorubicin · Drug: Vincristine · Drug: Prednisone

Interventions

  • Specified dose on specified days

    Also known as: BMS-986369, CC-99282

  • DrugPlacebo

    Specified dose on specified days

  • Specified dose on specified days

  • Specified dose on specified days

  • Specified dose on specified days

  • Specified dose on specified days

  • Specified dose on specified days

06

What researchers measure

Primary outcomes

  1. Progression-free survival (PFS) assessed by the Investigator

    Time frame: Approximately 24 months after the last participant's first treatment

Secondary outcomes

  1. PFS assessed by the Investigator

    Time frame: Approximately 24 months after the last participant's first treatment

  2. Overall survival (OS)

    Time frame: Up to approximately 67 months

  3. Event-free survival (EFS)

    Time frame: Approximately 24 months after the last participant's first treatment

  4. Complete Metabolic Response assessed by the Independent Response Adjudication Committee (IRAC)

    Time frame: Up to approximately 18 weeks

  5. Minimal residual disease (MRD) negativity rate

    Time frame: Up to approximately 18 weeks

  6. Progression-free survival (PFS) assessed by the IRAC

    Time frame: Approximately 24 months after the last participant's first treatment

  7. Objective response (OR) assessed by the Investigator

    Time frame: Up to approximately 18 weeks

  8. Complete metabolic response (CMR) assessed by the Investigator

    Time frame: Up to approximately 18 weeks

  9. PFS24 assessed by the Investigator 24 months after randomization

    Time frame: Up to 24 months

  10. Duration of response (DoR)

    Time frame: Up to approximately 67 months

  11. Second progression-free survival (PFS2) assessed by the Investigator

    Time frame: Up to approximately 67 months

  12. Relative dose intensity (%)

    Time frame: Up to 18 weeks

  13. Time from randomization to meaningful improvement in primary domains of interest in the European Organization for Research and Treatment of Cancer - Quality of Life C30 (EORTC QLQ-C30) Questionnaire

    Time frame: Up to approximately 67 months

  14. Time from randomization to meaningful improvement in primary domains of interest in the Functional Assessment of Cancer Treatment-Lymphoma (FACT-LymS) Questionnaire

    Time frame: Up to approximately 67 months

  15. Mean change from baseline in the EORTC QLQ-C30

    Time frame: Up to approximately 67 months

  16. Mean change from baseline in the FACT-LymS

    Time frame: Up to approximately 67 months

  17. Number of participants with Adverse Events (AEs)

    Time frame: Up to approximately 22 weeks

  18. Number of participants with treatment-emergent adverse events (TEAEs)

    Time frame: Up to approximately 22 weeks

  19. Number of participants with laboratory abnormalities

    Time frame: Up to approximately 22 weeks

  20. Number of participants with vital sign abnormalities

    Time frame: Up to approximately 22 weeks

07

Study locations

325 sites
  • Local Institution - 0014
    Mobile, Alabama 36604, United States
  • Local Institution - 0477
    Anchorage, Alaska 99508, United States
  • Local Institution - 0452
    Phoenix, Arizona 85054, United States
  • Local Institution - 0342
    San Francisco, California 94143, United States
  • Local Institution - 0497
    Fort Myers, Florida 33901, United States
  • Local Institution - 0287
    Jacksonville, Florida 32224, United States
  • Local Institution - 0415
    Margate, Florida 33063, United States
  • Local Institution - 0045
    Miami Beach, Florida 33140, United States
  • Local Institution - 0012
    Pensacola, Florida 32504, United States
  • Local Institution - 0502
    St. Petersburg, Florida 33705, United States
  • Local Institution - 0414
    Tampa, Florida 33612, United States
  • Local Institution - 0192
    West Palm Beach, Florida 33401, United States
  • Local Institution - 0485
    Weston, Florida 33331, United States
  • Local Institution - 0515
    Atlanta, Georgia 30303, United States
  • Local Institution - 0303
    Atlanta, Georgia 30322, United States
  • Local Institution - 0182
    Chicago, Illinois 60611, United States
  • Local Institution - 0048
    Skokie, Illinois 60077, United States
  • Local Institution - 0461
    Waukee, Iowa 50309, United States
  • Local Institution - 0031
    Westwood, Kansas 66205, United States
  • Local Institution - 0436
    Edgewood, Kentucky 41017, United States
  • Local Institution - 0408
    Baton Rouge, Louisiana 70809, United States
  • Local Institution - 0478
    Ann Arbor, Michigan 48109, United States
  • Local Institution - 0067
    Minneapolis, Minnesota 55407, United States
  • Local Institution - 0203
    Rochester, Minnesota 55905, United States
  • Local Institution - 0437
    Kansas City, Missouri 64132, United States
  • Local Institution - 0466
    Reno, Nevada 89511, United States
  • Local Institution - 0498
    East Brunswick, New Jersey 08816, United States
  • Local Institution - 0480
    Hackensack, New Jersey 07601, United States
  • Local Institution - 0049
    Morristown, New Jersey 07960, United States
  • Local Institution - 0175
    New Brunswick, New Jersey 08901, United States
  • Local Institution - 0190
    Buffalo, New York 14263, United States
  • Local Institution - 0451
    East Syracuse, New York 13057, United States
  • Local Institution - 0484
    New York, New York 10016, United States
  • Local Institution - 0369
    New York, New York 10028, United States
  • Local Institution - 0176
    New York, New York 10029, United States
  • Local Institution - 0174
    Chapel Hill, North Carolina 27599, United States
  • Local Institution - 0066
    Massillon, Ohio 44646, United States
  • Local Institution - 0450
    Tulsa, Oklahoma 74146, United States
  • Local Institution - 0179
    Portland, Oregon 97239, United States
  • Local Institution - 0009
    Pittsburgh, Pennsylvania 15232, United States
  • Local Institution - 0419
    York, Pennsylvania 17403, United States
  • Local Institution - 0435
    Fort Sam Houston, Texas 78234, United States
  • Local Institution - 0516
    Houston, Texas 77026, United States
  • Local Institution - 0046
    Houston, Texas 77030, United States
  • Local Institution - 0424
    Houston, Texas 77030, United States
  • Local Institution - 0293
    Richmond, Virginia 23298, United States
  • Local Institution - 0113
    Buenos Aires, Buenos Aires F.D. C1118AAT, Argentina
  • Local Institution - 0421
    Buenos Aires, Buenos Aires F.D. C1417DTB, Argentina
  • Local Institution - 0112
    Buenos Aires, 1426, Argentina
  • Local Institution - 0119
    Buenos Aires, C1426ANZ, Argentina
  • Local Institution - 0136
    Buenos Aires, C1431FWO, Argentina
  • Local Institution - 0111
    Córdoba, 5016, Argentina
  • Local Institution - 0357
    Gosford, New South Wales 2250, Australia
  • Local Institution - 0361
    Sydney, New South Wales 2560, Australia
  • Local Institution - 0358
    Westmead, New South Wales 2145, Australia
  • Local Institution - 0363
    Tiwi, Northern Territory 0810, Australia
  • Local Institution - 0356
    Birtinya, Queensland 4575, Australia
  • Local Institution - 0360
    Southport, Queensland 4215, Australia
  • Local Institution - 0365
    Frankston, Victoria 3195, Australia
  • Local Institution - 0362
    Heidelberg, Victoria 3084, Australia
  • Local Institution - 0359
    St Albans, Victoria 3021, Australia
  • Local Institution - 0364
    Warrnambool, Victoria 3280, Australia
  • Local Institution - 0385
    Wels, Upper Austria 4600, Austria
  • Local Institution - 0387
    Linz, 4020, Austria
  • Local Institution - 0386
    Vienna, 1140, Austria
  • Local Institution - 0255
    Fortaleza, Ceará 60115-281, Brazil
  • Local Institution - 0297
    Lago Sul, Federal District 71635580, Brazil
  • Local Institution - 0256
    Goiânia, Goiás 74605-020, Brazil
  • Local Institution - 0302
    Curitiba, Paraná 81520-060, Brazil
  • Local Institution - 0296
    Niterói, Rio de Janeiro 24020-096, Brazil
  • Local Institution - 0304
    Natal, Rio Grande do Norte 59075-740, Brazil
  • Local Institution - 0253
    Porto Alegre, Rio Grande do Sul 90110-270, Brazil
  • Local Institution - 0246
    Chapecó, Santa Catarina 89812-210, Brazil
  • Local Institution - 0247
    Joinville, Santa Catarina 89201260, Brazil
  • Local Institution - 0250
    Barretos, São Paulo 14784400, Brazil
  • Local Institution - 0249
    Jaú, São Paulo 17210-120, Brazil
  • Local Institution - 0301
    São José do Rio Preto, São Paulo 15090000, Brazil
  • Local Institution - 0248
    São Paulo, São Paulo 01323-903, Brazil
  • Local Institution - 0316
    São Paulo, São Paulo 01509-010, Brazil
  • Local Institution - 0298
    Rio de Janeiro, 22061-080, Brazil
  • Local Institution - 0294
    São Paulo, 01409-901, Brazil
  • Local Institution - 0252
    São Paulo, 04543-000, Brazil
  • Local Institution - 0317
    São Paulo, 05403-000, Brazil
  • Local Institution - 0251
    São Paulo, 05652-900, Brazil
  • Local Institution - 0393
    Plovdiv, 4002, Bulgaria
  • Local Institution - 0392
    Sofia, 1407, Bulgaria
  • Local Institution - 0394
    Sofia, 1431, Bulgaria
  • Local Institution - 0091
    Victoria, British Columbia V8R 6V5, Canada
  • Local Institution - 0153
    Montreal, Quebec H3T 1M5, Canada
  • Local Institution - 0073
    Montreal, Quebec H4J 1C5, Canada
  • Local Institution - 0004
    Sherbrooke, Quebec J1H 5N4, Canada
  • Local Institution - 0106
    Santiago, Santiago Metropolitan 7500921, Chile
  • Local Institution - 0107
    Santiago, Santiago Metropolitan 7580206, Chile
  • Local Institution - 0108
    Santiago, Santiago Metropolitan 7620002, Chile
  • Local Institution - 0110
    Santiago, Santiago Metropolitan 8320325, Chile
  • Local Institution - 0459
    Santiago, Santiago Metropolitan 8420383, Chile
  • Local Institution - 0164
    Viña del Mar, Valparaiso 0, Chile
  • Local Institution - 0195
    Beijing, Beijing Municipality 100091, China
  • Local Institution - 0236
    Chongqing, Chongqing Municipality 400016, China
  • Local Institution - 0196
    Chongqing, Chongqing Municipality 400030, China

Showing the first 100 of 325 sites across 38 countries. Choose a country and city above to see the rest.

08

References and documents

Individual participant data

Plan to share: Yes — BMS will provide access to individual anonymized participant data upon request from qualified researchers, and subject to certain criteria. Additional information regarding Bristol Myer Squibb's data sharing policy and process can be found at https://www.bms.com/researchers-and-partners/clinical-trials-and-research.html

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: See Plan Description

Access criteria: See Plan Description

Data sharing details ↗ · www.bms.com

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2024 (actual). Primary completion is estimated for Aug 2027, 37 months after the start.

Of 29 industry-sponsored phase 3 interventional studies under Lymphoma, half reached primary completion within 57 months of starting (the median), counting those still running; a quarter within 52 and three quarters within 69. This study's planned 37 months is below that.

Counting every sponsor, half of 62 studies reached it within 67 months; a quarter within 52 and three quarters within 106.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 27, 2024
First posted
Apr 10, 2024
StartActual
Jun 19, 2024
Primary completionEst.
Aug 9, 2027
CompletionEst.
Jun 26, 2029
Last update
Jul 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 6, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06356129
Lead sponsor
Celgene
Responsible party
Sponsor
First posted
Apr 10, 2024
Start date
Jun 19, 2024
Primary completion
Aug 9, 2027 (estimated)
Completion
Jun 26, 2029 (estimated)
Last update
Jul 6, 2026

Study contacts

Bristol-Myers Squibb
study director · Bristol-Myers Squibb

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Golcadomide

Start the discussion